Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection
October 23 2023 - 8:30PM
Business Wire
Agreement provides Quanterix a license to extensively studied
p-Tau 217 antibodies to enable global access to plasma-based
testing for Alzheimer’s Disease research and diagnostics
Quanterix Corporation (NASDAQ: QTRX), a leading provider of
ultra-sensitive research products and high-definition diagnostics,
today announced the signing of a license agreement with Janssen
Sciences Ireland UC (Janssen), a Johnson & Johnson (J&J)
Company. Under this agreement, Quanterix will receive worldwide,
non-exclusive rights to J&J’s extensively studied p-Tau 217
antibodies and assay designs for potential use in clinical research
and diagnostic products, further strengthening Quanterix’s position
at the forefront of the Alzheimer's Disease (AD) biomarker
field.
Under the terms of the license agreement, Janssen will grant
Quanterix a worldwide non-exclusive license for J&J-developed
technology to produce Simoa p-Tau 217 research-use only (RUO) assay
kits for global distribution. Furthermore, under the agreement
Quanterix will launch a Laboratory Developed Test (LDT) based on
the J&J p-Tau 217 antibodies and assay, offered through
Accelerator under the Lucent Diagnostics brand. These advances mark
a significant milestone for Quanterix's continued leadership in
advancing Alzheimer's Disease diagnosis and treatment, providing a
path for the first scalable immunoassay-based p-Tau 217 test to
potentially become widely available to researchers and
clinicians.
p-Tau 217 has emerged as a top performing biomarker for AD,
enabling clinical sensitivity and specificity in blood1. Highly
sensitive and specific blood-based biomarker tests may improve
diagnosis by expanding access to treatments for millions of
individuals with early Alzheimer’s Disease, which is currently
detected using positron emission tomography (PET) or lumbar
puncture for CSF biomarkers. These methods are expensive, lack wide
availability, and are invasive. There is growing consensus that
high performing blood-based biomarker tests may be an appropriate
alternative for patient care.
"This collaboration demonstrates the scientific advances that
are possible when Simoa’s ultra-sensitive detection is combined
with clinically validated antibodies and critical reagents,” said
Masoud Toloue, CEO of Quanterix. “Providing access to
high-performing blood-based p-Tau 217 assays are an important step
as we work with several partners to build the global infrastructure
for non-invasive testing of Alzheimer’s Disease.”
For more information about Quanterix’s work in neurology, visit:
https://www.quanterix.com/therapeutic-areas/neurology/.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive
biomarker detection is fueling breakthroughs only made possible
through its unparalleled sensitivity and flexibility. The Company’s
Simoa® technology has delivered the gold standard for earlier
biomarker detection in blood, serum or plasma, with the ability to
quantify proteins that are far lower than the Limit of
Quantification (LoQ) of conventional analog methods. Its
industry-leading precision instruments, digital immunoassay
technology and CLIA-certified Accelerator laboratory have supported
research that advances disease understanding and management in
neurology, oncology, immunology, cardiology and infectious disease.
Quanterix has been a trusted partner of the scientific community
for nearly two decades, powering research published in more than
2,000 peer-reviewed journals. Find additional information about the
Billerica, Massachusetts-based company at https://www.quanterix.com
or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on
Quanterix’s expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties. Factors that may cause Quanterix’s actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Quanterix’s filings with the U.S. Securities and Exchange
Commission, including the “Risk Factors” sections contained
therein. Except as required by law, Quanterix assumes no obligation
to update any forward-looking statements contained herein to
reflect any change in expectations, even as new information becomes
available.
1Brum WS, Cullen NC, Janelidze S, et al. A two-step workflow
based on plasma p-tau217 to screen for amyloid β positivity with
further confirmatory testing only in uncertain cases. Nat Aging.
2023;3(9):1079-1090
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231023933278/en/
Media: Maya Nimnicht, PAN Communications (510) 334-6273
pan.quanterix@pancomm.com Investor Relations: Ed Joyce, Quanterix
(610) 306-9917 ir@quanterix.com
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Apr 2023 to Apr 2024